Recent Progress in Cancer Therapeutics  by Mihich, Enrico & Zänker, Kurt S.
Meeting Report
Recent Progress in
Cancer Therapeutics
HRH Princess Chulabhorn Mahidol*, Enrico Mihich†
and Kurt S. Zänker‡
*Chulabhorn Research Institute, Bangkok, Thailand;
†Roswell Park Cancer Institute, Buffalo, NY, USA;
‡Institute of Immunology and Exp. Oncology,
Witten, Germany
From November 11 to 13, 2008, the Chulabhorn Research Insti-
tute welcomed approximately 450 scientists working in experimental
and clinical cancer research at the Chulabhorn Convention Center,
Bangkok, Thailand. Prof. Dr. HRH Princess Chulabhorn, Confer-
ence and Scientific Chairperson, together with the cochairpersons
Dr. Enrico Mihich (USA) and Dr. Kurt S. Zänker (Germany) and
with the Secretary General, Dr. Khunying Mathuros Ruchirawat,
designed a scientific program at the cutting edge of “Recent Progress
in Cancer Therapeutics.” The meeting was under the joint spon-
sorship of the American Association for Cancer Research (USA),
the Chulabhorn Research Institute (Thailand), the Fritz-Bender-
Foundation (Germany), and Mrs. Sybille Bartels-Hetzler (KPMG
Hamburg, Germany).
A Satellite Symposium on “Trends in Innate Immunity: the Com-
plement Cascade Proteins in Transplantation, Cancer and Hereditary
Angioedema” sponsored by the Network Complement Related Dis-
eases (NCRD, Luzern, Switzerland) preceded the main meeting.
Kurt S. Zänker (Witten, Germany) gave a short introduction into
innate immunity, which increasingly gains renewed interest, par-
ticularly because it became apparent that it is an evolutionary ancient
defense system. The phylogenetically ancient innate immune re-
sponse attacks infectious DNA/RNA carriers from the moment of
first contact and is the fundamental defensive weapon of unicellular
and multicellular organisms. Already the arthropods have a cellular
and humoral-based immune competence, which is mediated by
hemocytes, which resemble in development and function the cells
of the mammalian myeloid lineage. In mammalians, a broad variety
of different cell types exists that support the innate immune response.
Neutrophils, macrophages, dendritic cells, natural killer cells, and
eosinophilic granulocytes are important cellular components of the
innate immune response. The short- and long-distance communica-
tion between these cells and the regulatory links to adaptive immunity
take place by messenger molecules, such as cytokines, chemokines,
neurotransmitters, and hormones.
Recommended literature: Trends in Innate Immunity (2008). A
Egesten, A Schmidt, and H Herwald (Eds.). Contrib Microbiol. Karger,
Basel, Switzerland. vol 15.
Gilles Blancho (Nantes, France) spoke about the important role
of the innate immunity, with special reference to the complement sys-
tem in transplantation. Organ transplantation has become a major
therapeutic strategy to overcome organ failure. The alloimmune re-
sponse was considered for a long time as the almost unique in vivo
phenomenon to control acceptance and function of the graft; however,
it turned out that organ preservation, cold and warm ischemia, and the
activation of danger signals initiating a fast innate immune response,
including complement response, which concomitantly might start the
adaptive immune response, are important parameters that determine
graft survival or rejection.
Recommended literature: LeBas-Bernadet St and Blancho G
(2008). Current cellular immunological hurdles in pig-to-primate
xenotransplantation. Transpl Immunol. Oct 24 (Epub ahead of print).
Marco Cicardi (Milan, Italy) spoke about the acquired deficiency
of the C1 inhibitor. Angioedema due to the acquired deficiency of
the first component of human complement (C1-INH) is a rare syn-
drome usually identified as acquired angioedema (AAE). The clinical
features are subcutaneous, nonpruritic swelling without urticaria, in-
volvement of the upper respiratory tract, and partial obstruction of
the gastrointestinal tract causing abdominal pain. During the past
30 years, the group observed 34 patients with AAE for a median
follow-up period of 8 years. Ten of the 34 patients with AAE had no
apparent hematological disease at diagnosis or during follow-up. Eight
of them had anti–C1-INH autoantibodies and two had autoantibodies
and a nonhematologic malignancy. However, 11 of these patients pre-
sented non–Hodgkin lymphoma. The clinical coexistence of AAE and
B-cell malignancy or nonmalignant B-cell proliferation and pathogenic
autoimmune responses suggest that the etiopathogenesis of AAE is dom-
inated by an impaired control of B-cell proliferation; therefore, patients
with AAE should be closely monitored for lymphoproliferative diseases.
Recommended literature: Cicardi M, Zingale LC, Pappalardo E,
Folcioni A, and Agostoni A (2003). Autoantibodies and lymphoprolifera-
tive diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore)
82, 274–281.
A general discussion, led byM. Schata (Cologne, Germany), on the
functional role of complement in oncology closed the symposium. It
was discussed that pattern recognition receptors of innate immune cells
detect changes in glycosylation, which are concurrent with tumor de-
velopment and signals for complement activation and tumor cell lysis.
However, to avoid complement-mediated tumor cell lysis and elimi-
nation, many tumor types overexpress membrane-bound complement
inhibitors (CD46, CD55, and CD59) as well as factor H. Moreover,
some tumor types secrete matrix metalloproteinases, which can cleave
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C3b and liberate the deposited C3 fragment from tumor cells, thereby
preventing the efficient recognition by phagocytes and promoting
metastasis formation.
The main symposium started with the opening keynote lecture
delivered by Prof. Dr. HRH Princess Chulabhorn Mahidol. The
focus of HRH Princess Chulabhorn Mahidol’s lecture was on genetic
alterations in nasopharyngeal carcinoma (NPC) in the Thai popula-
tion. Her Royal Highness also emphasized the influence of living
environment on the risk of cancer development with an example of
school children, living in Bangkok, who have high levels of DNA ad-
ducts and impaired DNA repair mechanisms, thus having a higher risk
in developing cancer compared with children living in rural regions. In
Southeast Asia, esophageal cancer, liver cancer, and, above all, NPC, are
prevalent. Nasopharyngeal carcinoma has a marked geographical and
ethnic distribution; it is rare among whites in Western Europe and
North America. The disease is predominantly endemic in Southeast
Asia and southern China (30-50 cases/100,000/year). Nasopharyngeal
carcinoma is a multifactorial disease, and Epstein-Barr virus infection,
environmental factors, and genetic susceptibility are widely recognized
as risk factors. Genetic alterations in p53, exon 8, codon 273 have been
found in 33% of NPC patients, and therefore, detection of this p53
polymorphism may be a useful tool for screening of early NPC. A
molecular and clinical study is ongoing in Chiang Mai and Bangkok
to support this hypothesis.
Stephen Baylin (Baltimore, MD, USA) presented epigenetic modi-
fications as a major regulator of eukaryotic gene expression and aberrant
epigenetic silencing of gene expression, which contributes to tumori-
genesis. Both regional DNA methylation and global chromatin pack-
aging are interrelated partners that function in concert to control gene
transcription. In colon cancer tumor specimens, they found more than
300 genes hypermethylated and around 30 genes of the functional ex-
tracellular matrix hypermethylated at the same time; hypermethylation
means silencing of genes and has concomitantly a dramatic influence
on the performance and disease outcome of the patients. Hic-1 gene
codes for a transcription factor, regulated by p53, and was found to
be hypermethylated but not mutated. Aging, chronic injury and in-
flammation, and cell stress give rise to malignant clonal expansion,
when so-called “error zones of genes” are hypermethylated. The vision-
ary therapy options are as follows: 1) reversal of gene silencing, 2) re-
expression of key genes, and 3) correction of key pathways. Drugs that
kill tumor cells cause likely regrowth of tumors, whereas drugs killing
tumor stem cells will likely eradicate the tumor.
Recommended literature: Baylin SD (2008). Epigenetics and cancer.
In Molecular Basis of Cancer, 3rd ed. G Mendelsohn (Ed.). Saunders
Elsevier, Philadelphia, PA. pp. 57–65.
David W. Goodrich (Buffalo, NY, USA) talked about the role
of Thoc1 in prostate cancer. A problem in gene expression is that
the transcription initiation is imperfect; however, regulation of RNA
processing events through ribonuclear particles (mRNPs)–driven
mechanism may be important for coordinating the expression of func-
tionally related genes. His group investigates the potential role of regu-
lated mRNP biogenesis linked to carcinogenesis. They characterized
the effects of Thoc1 loss on a mouse model of prostate cancer. Thoc1
encodes an essential component of the evolutionary conserved TREX
complex, proteins accompanying the elongating RNA polymerase II
during transcription of some genes, and facilitate mRNP assembly
and the recruitment of RNA processing factors. It seems Thoc1 is re-
quired for prostate tumorigenesis initiated by Rb1 and p53 mutation.
Preliminary data suggest that Thoc1 may also be important in human
prostate cancer. Because cancer cells seem to be particularly sensitive to
Thoc1 loss, Thoc1 and the TREX complex may provide novel targets
for cancer therapy.
Recommended literature: Li Y, Lin AW, Zhang X,Wang Y, Wang X,
and Goodrich DW (2007). Cancer cells and normal cells differ in
their requirement of Thoc1. Cancer Res 67, 6657–6664.
Frank Thévenod (Witten/Germany) reported the role of the
Wnt/β-catenin signaling pathway in renal cancer induced by the
environmental contaminant cadmium. His group found out that
exposure of kidney proximal tubule cells to cadmium induces the
expression of the proto-oncogene c-Myc, the cell cycle regulator cyclin
D1, and the multidrug-resistant P-glycoprotein (Abcb1) owing to the
cadmium-dependent release of β-catenin from adherens junctions.
β-Catenin serves as a coactivator of the lymphoid enhancer factor/
T-cell factor (TCF) DNA-binding protein family. Using a luciferase
reporter plasmid for lymphoid enhancer factor/TCF binding sites, his
group found that cadmium increases luciferase activity in proliferat-
ing proximal tubule cells, whereas in quiescent confluent epithelia,
cadmium reduces basal luciferase activity. This suggests that cadmium
transactivates survival genes in proliferating cells only, which may be
caused by the predominance of TCF-activating molecular forms of
β-catenin. In contrast, in confluent cells, β-catenin–α-catenin dimers
may be released from adherence junction complex to inactivate tran-
scription. Using a luciferase reporter assay, Thévenod et al. also found
that cadmium-induced release of β-catenin also activates PITX2, a
bicoid-related homeodomain factor that regulates cell cycle control
genes. Unexpectedly, PITX2 was found to induce Abcb1 expression.
Hence, cadmium triggers β-catenin–dependent transcriptional re-
sponses of TCF and PITX2 to upregulate proliferation and cell survival
genes to promote carcinogenesis. Further characterization of both
pathways may ultimately contribute to the development of strategies
for cancer prevention and novel cancer therapeutics.
Recommended literature: Thévenod F, Wolff NA, Bork U, LeeWK,
and Abouhamed M (2007). Cadmium induces nuclear translocation
of b-catenin and increases expression of c-myc and Abcb1a in kidney
proximal tubule cells. Biometals 20, 807–820.
Peter A. Jones (Los Angeles, CA, USA) continued on the epigenetics
of cancer addressing the future of epigenetic therapy. It becomes in-
creasingly clear that the epigenetic silencing of growth-regulating genes
by methylation of CpG islands located in the promoters of devel-
opmental genes represents a common pathway for their inactivation.
DNA methylation patterns are somatically heritable over a lifetime.
In principle, there are three pathways silencing tumor suppressor genes:
1) adopting a chromatin configuration that is associated with increased
binding of methyl binding proteins (nucleosome remodeling), 2) in-
creasing the methylation of lysine 9 residue of histone H3, and 3)
increasing methylation of cytosine residues in human DNA. These
pathways can be interfered and rapidly reversed by transient treatment
with 5-aza-2′-deoxcytidine. However, gene expression is not permanent
because methylation tends to reoccur in the promoter regions. More re-
cently, the group has focused on the stable cytidine analog, zebularine,
which is incorporated into DNA and forms covalent bond with DNA
methyltransferase enzymes. The drug also results in a strong knock-
down in the level of active DNA methyltransferase protein and showed
reexpression of silenced tumor suppressor genes in human tumor
xenografts growing in nude mice. For chronic treatment of human
cancers, the clinical problems of dosages and time of application, the
resilencing of activated suppressor genes, and the drug instability have
to be solved.
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Recommended literature: Jones PA and Baylin SB (2002). The fun-
damental role of epigenetic events in cancer. Nat Rev Genet 3, 415–428.
Alain Sarasin (Villejuif, France) spoke about the overexpression of
some DNA repair pathways associated with metastasis risk in mela-
noma patients. Using a collection of 83 frozen human primary cuta-
neous melanomas, his group determined their genome-wide gene
expression profiles. Alain’s group identified a signature of 254 genes
allowing to predict with a high probability distant metastasis-free
survival as well as overall survival at 4 years; most of the genes were
correlated with thickness or the tumor. Using a newly developed bio-
informatic tool to analyze the differential gene expression by looking at
whole biological pathways, the following most significant pathways
associated with progression to metastasis were found: 1) DNA replica-
tion and 2) DNA repair pathways. It was found that 46 genes of the
DNA repair pathway were associated with metastatic progression and
poor prognosis. Few genes were directly involved in nucleotide ex-
cision repair, base excision repair, and mismatch repair. This over-
expression of repair genes explains nicely the extraordinary resistance
of metastatic melanoma to chemotherapy and radiotherapy.
Recommended literature: Sarasin A and Kauffmann A (2008).
Overexpression of DNA repair genes is associated with metastasis:
a new hypothesis. Mutat Res 65, 49–55.
Feyruz Rassool (Baltimore, MD, USA) talked about the inhibition
of double-strand break (DSB) repair and alternative nonhomologous
end-joining (NHEJ): potential therapeutic targets in chronic myeloid
leukemia (CML) with resistance to imatinib. Her group found that ge-
nomic instability in myeloid malignancies may be driven by a combi-
nation of ongoing constitutive DNA damage coupled with increased
frequencies of the error-prone NHEJ, which results in improper re-
pair of DSBs. BCR-ABL fusion tyrosine kinase in CML induces high
levels of radical oxygen species that generate DSBs. The CML cells
repair DSBs by aberrant NHEJ that is characterized by large DNA
deletions. Imatinib that targets BCR-ABL is the criterion standard of
therapy in CML patients. However, it has become clear that patients
become resistant to imatinib and other tyrosine kinase inhibitors, such
as dasatinib and nilotinib. Therefore, there is an urgent need for alter-
native therapeutic targets for patients resistant to tyrosine inhibitors.
The main proteins involved in alternative NHEJ, which include
DNA ligase IIIα, x-ray repair cross-complementing gene 1 protein,
DNA ligase I, poly (ADP-ribose) polymerase, andWerner-RecQ helicase
have the potential to be novel therapeutic targets in CML patients that
have acquired resistance to imatinib.
Recommended literature: Rassool FV, Gaymes TJ, Omidavar N,
Brady N, Beurlet S, Pla M, Reboul M, Lea N, Chomenne C, Thomas
NSB, et al. (2007). Reactive oxygen species: DNA damage and error-
prone repair: a model for genomic instability with progression in mye-
loid leukemia. Cancer Res 67, 8762–8771.
Robert A. Weinberg (Cambridge, MA, USA) delivered a keynote
address on the mechanisms of malignant progression. He gave a
magnificent overview on the mechanisms of malignant progression,
extending the Vogelstein model of carcinogenesis by addressing four
major questions with respect to metastasis formation: 1) is the de-
velopment of metastases a selective or adaptive process? 2) what are
rate limiting determinants of metastases?, 3) do cancer cells learn to
colonize while in the primary tumor (cell-of-origin) or at the sites of dis-
semination?, and 4) does a partial or complete epithelial-mesenchymal-
transition program underlie the invasive/metastatic phenotype of all
high-grade human tumors? He spoke on cancer stem cells and, most
importantly, on evidences of the redifferentiation of non–stem cells
into cancer stem cells. This has the tremendous implication in cancer
chemotherapy because both cell types, cancer stem cells and non–stem
cells, have to be eradicated therapeutically to prevent tumor regrowth
and metastasis formation. This concept is an answer to why cancer is
so difficult to treat. The race to identify stem cells and cancer stem cells
in all different kinds of tumors is now open. The findings and molec-
ular discoveries of differentiation and redifferentiation processes of
cancer stem cells and non–stem cells will undoubtedly revolutionize
our understanding of how cancer develops.
Recommended literature: Weinberg RA (2007). The Biology of
Cancer. Taylor & Francis, Garlan Science.
Li Yang (Nashville, TN, USA) addressed transforming growth
factor β (TGF-β) as a regulator of the tumor microenvironment.
Transforming growth factor β is known to work as both a tumor sup-
pressor and a tumor promoter; therefore, it is most important to find
out what factors mediate this switch in function and when this
switch occurs. Loss of TGF-β signaling decreases tumor latency,
enhances metastasis formation, and is associated with the recruitment
of Gr-1/CD11b–positive cells to the tumor microenvironment. In
early tumor development, TGF-β activates smad signaling, whereas
in late tumor development, there is non-smad signaling predominant.
Interestingly, the point of preseeding of myeloid cells (Gr-1/CD11b–
positive) is at premetastasis lesions.
Recommended literature: Yang L and Moses HL (2008). Trans-
forming growth factor β: tumor suppressor of promoter? Are host
immune cells the answer? Cancer Res 68, 9107–9111.
Frank Entschladen (Witten, Germany) reported on a metastasis-
promoting function of the neurotransmitter norepinephrine, investi-
gated in nudemice. His group provided evidence for a newly discovered
interaction of the tumor with the nervous system in analogy to neo-
angiogenesis. Tumor cells release nerve growth and nerve guidance
factors by which the tumor establishes its own innervation, a process
termed neo-neurogenesis and, as overall related to cancer more specifi-
cally, cancer-associated neurogenesis. Norepinephrine, as one neuro-
transmitter, senses the expressed β2-adrenoreceptors at the surface of
the tumor cells, thereby initiating a signal cascade through adenyl cy-
clase and protein kinase A to activate the transcription factors cAMP-
response element binding protein, activating transcription factor 1, and
nuclear factor κ B, which promote proliferation and metastasis for-
mation. The major strength of his presentation is the novelty combin-
ing experimental, translational, and epidemiological research and that
the neuroparacrine microenvironment of a tumor opens a new gateway
for therapeutic approaches.
Recommended literature: Zaenker KS and Entschladen F (Eds.)
(2007). Neuronal Activity in Tumor Tissue. In Progr Exp Tumor Res.
Bertino JR (Series Ed.). Karger, Basel, Switzerland. Vol. 39.
Niramol Savaraj (Miami, FL, USA) spoke about amino acid dep-
rivation, autophagy, and apoptosis. The triple A’s—as targets in cancer
therapy. She stressed that within the classic biochemical pathways of
glucose, amino acid, and fatty acid metabolisms, a few key enzymes
and substrates can be targeted therapeutically because of the differences
in activities between tumor and normal cells. Individuals with meta-
static melanoma have a poor prognosis, and many human melanomas
are auxotrophic for arginine, and arginine is not an essential amino
acid in humans; this auxotrophy might be therapeutically exploited.
A novel formulated amino acid–degrading enzyme, arginine deiminase
(ADI), was used to lower plasma arginine in melanoma patients with
advanced disease. Autophagy is a lysosomal-based pathway, which
leads, when in excess, activated to cell death. From experimental data
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with melanoma cells, it was evident that ADI can induce cell death
through autophagy and apoptosis. Within phases 1 and 2 studies with
ADI, 6 of 24 patients with advanced melanoma responded to treat-
ment (partial remission, 5/25; complete remission, 1/24). Elimination
of all detectable plasma arginine in patients with metastatic mela-
noma was well tolerated and may be effective in the therapy for meta-
static melanoma.
Recommended literature: Savaraj N, You M, Wu C, Marini M,
Kuo T, Wangpaichitr M, Bomalaski L, and Feun G (2008). Arginine
deprivation for the treatment of advanced melanoma: Clinical results/
correlation with argininosuccinate synthetase (ASS) expression. J Clin
Oncol 26, Abstract. 2019.
Alberto Mantovani (Milan, Italy) gave a talk on inflammation
and cancer because there is broad spectrum of evidences on the inter-
action of inflammatory processes and cancer, e.g., 1) colitis may by
associated with cancer by TIR8, 2) D6 acts as a gatekeeper for inflam-
matory CC chemokines, 3) increased damage of colon mucosa in
D6−/− mice by chronic inflammation gives rise to increased num-
bers of tumors, 4) pancreatic tumor cells expressing the fractalkine/
neurotactin CX3C receptor1, when engaged, are protected from apop-
tosis and are forced to migrate, and when expressed in pancreas
carcinoma in vivo, the tumor shows neuronal invasion; CX3CR1 ex-
pression correlates with malignancy of tumors. He explained the path-
ways through nuclear factor κ B, Stat, and hypoxia-inducing factor of
inflammatory cells, leading to cancer-related inflammation and chronic
inflammatory microenvironment of cancer. For inflammatory cells, he
considered macrophages as key orchestrators of chronic inflammation
responding to genetic and functional programs. M1 macrophages,
which are classically activated by microbial products and interferon,
are potent effector cells that kill microorganisms and tumors. In con-
trast, M2 macrophages tune inflammation and adaptive immunity,
promote cell proliferation by producing growth factors and products
of the arginase pathway, and express scavenger receptors, promote
angiogenesis and tissue remodeling and repair. M2 polarization of
phagocytes represents the dark side of the immune competence in re-
spect to proinflammatory human tumor programs.
Recommended literature: Mantovani A (2005). Cancer inflamma-
tion by remote control. Nature 435, 752–753.
Soldano Ferrone (Pittsburgh, PA, USA) introduced a Listeria-
based vaccine against high molecular weight–melanoma-associated
antigen (HMW-MAA), also known as melanoma chondroitin sulfate
proteoglycan. This antigen is expressed on the cell surface of mela-
noma cells, cancer stem cells, and tumor-activated pericytes and has a
restricted distribution in normal tissues. A fragment of HMW-MAA
(residues 2160-2258) was cloned in frame to the first 441 residues
of the Listeriolysin O protein to be secreted by a recombinant Listeria
monocytogenes (Im-LLO-HMW-MAA-C). Immunization with this vac-
cine was able to impede tumor growth of early established B16F10
HMW-MAA tumors inmice, and both CD4- and CD8-positive T cells
were required for therapeutic efficacy. In conclusion, this novel immune
therapeutic approach with a Listeria-based vaccine against HMW-MAA
can trigger cell-mediated immune response to this antigen and can also
target pericytes reducing these cells in numbers in the tumor vascula-
ture, which are important for tumor angiogenesis.
Recommended literature: Maciag PC, SeaveyMM, Pan ZK, Ferrone
S, and Patterson Y (2008). Cancer immunotherapy targeting the high
molecular weight melanoma-associated antigen protein results in an
anti-tumor response and reduction of pericytes in the tumor vasculature.
Cancer Res 68, 8066–8075.
Michael Rossbach (Singapore, Singapore) introducedDicer-deficient
mouse embryonic stem cells that were rescued with the two Dicer pro-
teins from Drosophila melanogaster, dcr-1 and dcr-2. This resulted in
a structure and function analysis of Dicer with the potential of specifi-
cally rescuing either the miRNA or the siRNA pathway. Having em-
bryonic stem cells on hand, that now either process miRNA or siRNA
helps to study the involvement of individual small RNA in tumori-
genesis. Three of the best-understood mRNA, namely, lin-4, let-7, and
bantam, regulate cell division and differentiation. In cancer, numerous
miRNA are altered, and in let-7 mutants, the cells fail to terminally dif-
ferentiate and keep on dividing. In lung cancer cells, let-7 expression
was found to be significantly lower than in normal lung tissue. The loss
of the miRNA regulation of the ras oncogenes could lead to ras over-
expression. In contrast, overexpression of let-7 results in a down-regulation
in ras expression—a vision for new strategies in lung cancer therapy.
For the development of new therapies to target cancer cells and cancer
stem cells, which are chemoresistant, miRNA could push stem cells to
become more differentiated and less tumorigenic through switching off
particular genes.
Recommended literature: Rossbach M (2007). Dissecting RNA
Mediated Gene Silencing Pathways In Murine Embryonic Stem Cells
[dissertation]. University Witten/Herdecke, Germany.
Kurt S. Zänker (Witten, Germany) summarized the meeting and re-
ferred to the Opening Address by Prof. Dr. HRH Princess Chulabhorn
Mahidol that “this meeting has been organized to inaugurate the
Chulabhorn Cancer Center and to carry forward the spirit of coop-
eration and collaboration. It should serve to further encourage and
enhance our endeavors in an area of vital importance to the health
and well being of human mankind.” These meeting days and the re-
sults were well embedded within this aforementioned scientific and
social scope.
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